Robert Sobol

CEO, MultiVir Inc.

Robert E. Sobol, M.D. has pioneered the development of novel biological cancer therapies and is an internationally renowned physician-scientist in the fields of molecular cancer treatments and biomarkers. He is among the first physcians to treat cancer patients with monoclonal antibodies and gene therapy. He was a co-founder of Biogen-Idec which is one of the world’s largest biotechnology companies and pioneered the use of monoclonal antibodies for cancer treatment. Dr. Sobol led the research teams responsible for the first experimental immune gene therapies for the treatment of brain tumors and colon carcinoma. He is a founder and CEO of MultiVir Inc., a company developing cancer gene therapies. He was the founding Editor-in-Chief of Cancer Gene Therapy, a Nature Publishing Group journal. Dr. Sobol was affiliated with the Sidney Kimmel Cancer Center in San Diego since its inception in 1990 where he served in various scientific and management capacities. Dr. Sobol is a past President of the International Society of Cell and Gene Therapy for Cancer and has served on the Clinical Program Review Committee of the National Cancer Institute.

Dr. Sobol received a B.A. in Philosophy from Boston University and a M.D. from The Chicago Medical School. He subsequently trained at the University of Southern California Medical Center and at the University of California, San Diego and received Board Certifications in Internal Medicine and Medical Oncology.